Promising immunotherapies with Th1-related cytokines against infectious diseases.
Promising immunotherapies with Th1-related cytokines against infectious diseases.
复制标题
DOI：
10.1007/s10156-003-0263-5
复制
发表时间：
2003-09-01
影响因子：
2.2
通讯作者：
Kawakami, Kazuyoshi
中科院分区：
文献类型：
--
作者：
Kawakami, Kazuyoshi
近年来，免疫系统受损的个体数量有所增加。这是由于老年人、器官移植后接受免疫抑制治疗的患者、恶性血液病患者和艾滋病患者人数的增加。由于向Th 2主导状态转变，这些人经常陷入辅助性T细胞（Th）1-Th 2细胞因子失衡。这种病理状况使他们处于发展由各种微生物病原体引起的感染性疾病的高风险中，这些病原体通常是常规化疗难以治疗的。因此，Th 1相关的细胞因子的管理是有希望的免疫治疗对这些难治性感染性疾病。在一系列的研究中，我们已经证明了治疗与Th 1相关的细胞因子，如干扰素（IFN）-γ，白细胞介素（IL）-12，IL-18，在保护动物免受实验感染性疾病引起的结核分枝杆菌和新型隐球菌。最近，一些研究者报道了IFN-γ或IL-12在难治性结核性和非结核性分枝杆菌病患者中的成功临床治疗。因此，现在是进行科学评估的适当时机，以在临床上确认这些新型免疫疗法的有效性。
In recent years, there has been an increase in the number of individuals with compromised immune systems. This is due to the rise in the numbers of aging people, patients receiving immunosuppressive treatment after organ transplantation, patients with hematological malignancies, and patients with AIDS. These individuals frequently fall into helper T cell (Th)1-Th2 cytokine imbalance due to a shift towards a Th2-dominant condition. Such a pathological condition puts them at a high risk for developing infectious diseases caused by a variety of microbial pathogens which are often refractory to conventional chemotherapy. Therefore, the administration of Th1-related cytokines is expected to be promising immunotherapy against these intractable infectious diseases. In a series of investigations, we have demonstrated the effectiveness of treatment with Th1-related cytokines, such as interferon (IFN)-gamma, interleukin (IL)-12, and IL-18, in protecting animals from experimental infectious diseases caused by Mycobacterium tuberculosis and Cryptococcus neoformans. Recently, several investigators reported successful clinical treatment with IFN-gamma or IL-12 in patients with intractable tuberculous and nontuberculous mycobacteriosis. Thus, now is an appropriate time for scientific evaluation to clinically confirm the effectiveness of these novel immunotherapies.